# OnCo record nct04639219 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04639219/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04639219", "NCT04639219" ;
  schema:name "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations"@en ;
  schema:description "A phase 2 trial of Trastuzumab deruxtecan in melanoma, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04639219/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04639219> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2020-12-30" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04639219-lancet-oncol-2024/> .